ADCLimited DatastaleBiying ChenPhase 2
sacituzumab govitecan (Trodelvy, Sacituzumab Tirumotecan Plus Immune Checkpoint Inhibitor)
Recurrent or Metastatic Head and Neck Carcinoma · MET
#MET#ADC#Phase2#antibody-drug-conjugate#RecurrentorMetastaticHeadandNeck+1
Trials 1Status Recruiting